Here are the 10-Q quarterly reports from electroCore, Inc. (ECOR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ECOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ECOR filings page.
electroCore, Inc. reported third-quarter 2026 net sales of $9.690 million, up 12% from $8.689 million a year earlier, while net loss narrowed to $1.339 million from $3.405 million. For the first nine months, sales were $28.724 million versus $22.789 million, and net loss was $9.669 million versus $10.931 million.
Cash, cash equivalents and marketable securities totaled $7.5 million at September 30, 2026. Operating activities used $9.355 million during the nine months, compared with $6.647 million a year earlier. Management said forecast cash falls short of planned operating, investment and capital-expenditure needs for at least the next 12 months from issuance, raising substantial doubt about the company’s ability to continue as a going concern. Lovell represented 62.6% of third-quarter net sales; beginning in August 2026, electroCore implemented a change to transition all prescription product sales to the VA and Department of Defense through Lovell.
In October 2026, electroCore submitted a 510(k) premarket notification seeking FDA clearance of Quell for chronic chemotherapy-induced peripheral neuropathy. Under its Sales Agreement, the company sold 505,346 shares during the nine months for approximately $4.0 million in net proceeds after $0.3 million in issuance costs.
electroCore, Inc. reported strong top-line growth but ongoing losses and liquidity risk for the quarter ended March 31, 2026. Net sales rose 43% year over year to $9.6 million, driven mainly by U.S. prescription devices, especially sales to the Department of Veterans Affairs.
Gross margin improved to 87%, yet operating expenses increased to $13.7 million, leading to a net loss of $5.3 million and a stockholders’ deficit of $5.7 million. Cash, cash equivalents and marketable securities totaled $8.8 million, and management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional capital or cost reductions.
electroCore (ECOR) reported higher Q3 results but remained unprofitable. Net sales were $8.689 million for the quarter, up from $6.554 million a year ago, driven by prescription devices and wellness products. Gross profit was $7.470 million, offset by operating expenses of $10.354 million, resulting in a net loss of $3.405 million, or $0.40 per share. For the nine months, net sales reached $22.789 million versus $18.136 million.
Liquidity improved with cash, cash equivalents, restricted cash and marketable securities totaling $13.201 million as of September 30, 2025. Long‑term debt stood at $6.526 million after a $7.5 million Avenue term loan bearing at least 12.50% interest, with up to $2.5 million convertible at $8.4625 per share and a potential additional $4.5 million Tranche 2. Stockholders’ equity shifted to a deficit of $1.073 million. Sales to the U.S. Department of Veterans Affairs accounted for 69.9% of Q3 net sales. The company also maintains a $20 million ATM program and a $100 million shelf.